Honokiol radiosensitizes colorectal cancer cells: enhanced activity in cells with mismatch repair defects
Open Access
- 1 November 2011
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 301 (5), G929-G937
- https://doi.org/10.1152/ajpgi.00159.2011
Abstract
DNA mismatch repair is required for correcting any mismatches that are created during replication and recombination, and a defective mismatch repair system contributes to DNA damage-induced growth arrest. The colorectal cancer cell line HCT116 is known to have a mutation in the hMLH1 mismatch repair gene resulting in microsatellite instability and defective mismatch repair. Honokiol is a biphenolic compound that has been used in traditional Chinese medicine for treating various ailments including cancer. This study was designed to test the hypothesis that honokiol enhances the radiosensitivity of cancer cells with mismatch repair defect (HCT116) compared with those that are mismatch repair proficient (HCT116-CH3). We first determined that the combination of honokiol and γ-irradiation treatment resulted in dose-dependent inhibition of proliferation and colony formation in both cell lines. However, the effects were more pronounced in HCT116 cells. Similarly, the combination induced higher levels of apoptosis (caspase 3 activation, Bax to Bcl2 ratio) in the HCT116 cells compared with HCT116-CH3 cells. Cell cycle analyses revealed higher levels of dead cells in HCT116 cells. The combination treatment reduced expression of cyclin A1 and D1 and increased phosphorylated p53 in both cell lines, although there were significantly lower amounts of phosphorylated p53 in the HCT116-CH3 cells, suggesting that high levels of hMLH1 reduce radiosensitivity. These data demonstrate that honokiol is highly effective in radiosensitizing colorectal cancer cells, especially those with a mismatch repair defect.Keywords
This publication has 42 references indexed in Scilit:
- Synergistic Role of Curcumin With Current Therapeutics in Colorectal Cancer: MinireviewNutrition and Cancer, 2009
- Honokiol, a Multifunctional Antiangiogenic and Antitumor AgentAntioxidants and Redox Signaling, 2009
- Phase specific functions of the transcription factor TFII-I during cell cycleCell Cycle, 2009
- Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation ScreeningCancer Epidemiology, Biomarkers & Prevention, 2008
- MLH1 Deficiency Enhances Radiosensitization with 5-Fluorodeoxyuridine by Increasing DNA MismatchesPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2008
- Surgical Therapy for Colorectal AdenocarcinomaGastroenterology Clinics of North America, 2008
- Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicityExperimental & Molecular Medicine, 2008
- The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic inventionMolecular Cancer, 2007
- Studies of the cell cycle regulatory proteins P16, cyclin D1 and retinoblastoma protein in laryngeal carcinoma tissueThe Journal of Laryngology & Otology, 2004
- Defective Mismatch-Repair Colorectal Cancer Clinicopathologic Characteristics and Usefulness of Immunohistochemical Analysis for DiagnosisAmerican Journal of Clinical Pathology, 2004